REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
636.34 USD   -1.91%
04:14pREGENERON PHARMACEUTICALS : Statement of Changes in Beneficial Ownership - Form 4
PU
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron : FDA to Review Extended Eylea Regimen in Diabetic Retinopathy

06/29/2022 | 06:24am EDT

By Colin Kellaher


Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration will review its application seeking approval of an extended dosing of its blockbuster eye treatment Eylea.

The Tarrytown, N.Y., biotechnology company said the application covers Eylea injection for every 16-week dosing in patients with diabetic retinopathy, the leading cause of blindness among working-age adults in the U.S.

Regeneron said the extended regimen, if approved, would provide a longer treatment interval and additional dosing flexibility for Eylea, which won FDA approval for four- and eight-week dosing regimens in 2019.

Regeneron, which reported U.S. Eylea sales of nearly $5.8 billion last year, said the FDA set a target action date of Feb. 28, 2023, for a decision on the 16-week regimen.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

06-29-22 0824ET

All news about REGENERON PHARMACEUTICALS, INC.
04:14pREGENERON PHARMACEUTICALS : Statement of Changes in Beneficial Ownership - Form 4
PU
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Main..
MT
08/04Morgan Stanley Raises Regeneron Pharmaceuticals' Price Target to $625 From $619, Mainta..
MT
08/04Regeneron Pharmaceuticals - NOVEL COSTIMULATORY BISPECIFIC ANTIBODY SHOWS ENCOURAGING A..
AQ
08/04RBC Raises Price Target on Regeneron Pharmaceuticals to $647 From $640, Maintains Secto..
MT
08/03Wall Street rises on tech, earnings boost as recession fears ease
RE
08/03GLOBAL MARKETS LIVE : Airbnb, Infineon, PayPal, Moderna, Starbucks...
MS
08/03Regeneron Pharmaceuticals Up Over 7%, on Pace for Largest Percent Increase Since June 2..
DJ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 798 M - -
Net income 2022 3 807 M - -
Net cash 2022 4 839 M - -
P/E ratio 2022 18,9x
Yield 2022 -
Capitalization 69 351 M 69 351 M -
EV / Sales 2022 5,47x
EV / Sales 2023 4,55x
Nbr of Employees 10 715
Free-Float 80,5%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 648,70 $
Average target price 676,32 $
Spread / Average Target 4,26%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.2.72%69 351
GILEAD SCIENCES, INC.-8.65%83 136
VERTEX PHARMACEUTICALS37.98%77 707
WUXI APPTEC CO., LTD.-22.47%38 993
BIONTECH SE-37.79%38 973
GENMAB A/S0.72%23 679